2137 — Brii Biosciences Balance Sheet
0.000.00%
Last trade - 00:00- HK$1.04bn
- -HK$1.23bn
- CNY18.61m
Annual balance sheet for Brii Biosciences, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 3,355 | 2,997 | 2,661 | 2,320 | 1,940 |
| Net Total Receivables | 51.5 | 57.7 | 71.1 | — | — |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 3,414 | 3,077 | 2,783 | 2,414 | 1,963 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 33.4 | 19.5 | 5.61 | 14.3 | 14.2 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 3,612 | 3,392 | 3,198 | 2,707 | 2,360 |
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 281 | 229 | 126 | 77.4 | 32.3 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 269 | 197 | 79.2 | 49.7 | -16.1 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 3,343 | 3,195 | 3,119 | 2,657 | 2,376 |
| Total Liabilities & Shareholders' Equity | 3,612 | 3,392 | 3,198 | 2,707 | 2,360 |
| Total Common Shares Outstanding |